L Van Gaal, X Pi-Sunyer, JP Després, C … - Diabetes Care, 2008 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—The RIO studies enrolled patients who were either
overweight (BMI >27 kg/m 2 ) with at least one comorbidity (ie, hypertension,
dyslipidemia, or, for RIO-Diabetes, type 2 diabetes) or obese. All patients ... Cited by 68 - Related articles - BL Direct - All 5 versions
X Pi-Sunyer, JP Despres, A Scheen - Diabetes Care, 2008 - Am Diabetes Assoc OBJECTIVE — To better define the efficacy and safety of rimonabant, the first
selective cannabinoid type 1 (CB 1 ) receptor antagonist, in a large population
of overweight and obese patients using pooled efficacy data from three ... Cited by 1 - Related articles - All 3 versions
- ►nursing2008.com SE Nissen, SJ Nicholls, K Wolski, J Rodes- … - Jama, 2008 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. Cited by 98 - Related articles - BL Direct - All 5 versions
- ►oxfordjournals.org LF Van Gaal, AJ Scheen, AM Rissanen, S … - European Heart Journal, 2008 - Eur Soc Cardiology Methods and results: Patients with a body mass index 30 or >27 kg/m 2 with
treated/untreated hypertension, dyslipidaemia, or both, were randomized to
double-blind treatment with placebo, rimonabant 5 or 20 mg once daily plus ... Cited by 28 - Related articles - All 9 versions
M Gary-Bobo, G Elachouri, JF Gallas, P Janiak, … - Hepatology, 2007 - interscience.wiley.com This study investigated the effects of rimonabant (SR141716), an antagonist of
the cannabinoid receptor type 1 (CB1), on obesity-associated hepatic steatosis
and related features of metabolic syndrome: inflammation (elevated plasma ... Cited by 100 - Related articles - BL Direct - All 4 versions
M Cote, I Matias, I Lemieux, S Petrosino, N … - International Journal of Obesity, 2007 - nature.com Plasma 2-AG, but not AEA, levels correlated positively with BMI, waist girth,
IAA measured by computed tomography, and fasting plasma triglyceride and insulin
levels, and negatively with high-density lipoprotein cholesterol and ... Cited by 77 - Related articles - BL Direct - All 4 versions
A Schäfer, J Pfrang, J Neumüller, S Fiedler, G … - British Journal of Pharmacology, 2008 - pubmedcentral.nih.gov Rimonabant (10 mg kg −1 by gavage) was fed for 2 weeks to 3-month-old male
obese Zucker rats as an impaired glucose tolerance model and for 10 weeks to
6-month-old male obese Zucker rats as a model of the metabolic syndrome. ... Cited by 16 - Related articles - All 4 versions
LM Ruilope, JP Després, A Scheen, X Pi- … - Journal of Hypertension, 2008 - journals.lww.com Objective: Rimonabant, the first selective cannabinoid type 1 (CB 1 ) receptor
blocker, has been shown to improve multiple cardiometabolic risk factors in
overweight/obese patients. This analysis assessed the impact of rimonabant ... Cited by 32 - Related articles - BL Direct - All 5 versions
- ►cell.com C Addy, H Wright, K Van Laere, I Gantz, N … - Cell metabolism, 2008 - Elsevier Cannabinoid 1 receptor (CB1R) inverse agonists are emerging as a potential
obesity therapy. However, the physiological mechanisms by which these agents
modulate human energy balance are incompletely elucidated. Here, we ... Cited by 67 - Related articles - All 7 versions
- ►nll.se [PDF] R Christensen, PK Kristensen, EM Bartels, H … - The Lancet, 2007 - Elsevier Patients given rimonabant had a 4·7 kg (95% CI 4·1–5·3 kg; p<0·0001)
greater weight reduction after 1 year than did those given placebo. Rimonabant
caused significantly more adverse events than did placebo (OR=1·4; ... Cited by 198 - Related articles - All 32 versions
